© 2022 MJH Life Sciences and Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ , Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
July 20, 2013
Patients with previously treated multiple myeloma responded well to therapy with the monoclonal antibody elotuzumab in combination with lenalidomide and low-dose dexamethasone, with a high objective response rate and longer progression-free survival (PFS) in those who received the dose being taken into phase III studies.
June 01, 2013
An investigational monoclonal antibody called daratumumab has received breakthrough therapy designation from the FDA for the treatment of patients with double refractory multiple myeloma, according to a statement from the drug's manufacturer, Janssen Biotech.